Nature of business: Any lawful purpose. Thought provoking!

PRINCIPAL OFFICE
Phone:
206-992-4126
Email:
CAMBALAM@GMAIL.COM[/]i
Street Address:
7725 31ST AVE NW, SEATTLE, WA, 98117-4643, UNITED STATES

Search Cambalam and you’ll learn that it’s in Guatemala. Guatemala has abundant mineral reserves that include uranium, sand and gravel, nickel, limestone, petroleum, coal, gold, silver, copper, iron ore and cobalt.

🤔

Reviewing a thread, I came across your post which I never responded to.

The answer is unlawful theft/charter termination. It doesn’t absolve you after the fact but that’s why the law was changed. Holding companies are now game but WMI should never have been touched.

Sure, no problem.

Ron,

I think you need to read my post again because I don’t think you understood it.

rwdutch,

I posted that because some have said that the FDIC is recouping funds to plug a multi-billion dollar hole in WAMU’s balance sheet. If that were the case, then the FDIC would not be able to post that the resolution of WAMU through the P&A Agreement was completed at no cost to the Deposit Insurance Fund.

Following the FDIC’s statement, the question arises about why the Receivership is still open if assets and other expected returns don’t exist and are not anticipated. And yes, LIBOR lawsuits against the big banks are currently outstanding.

The reality is the FDIC considered WAMU a failed bank due to a run on deposits and so called concern about its loan portfolio. However, according to the signed letter (dated 9/25/08) presented by WAMU regarding its plan to raise capital and boost liquidity, it had 0 derivative exposure and had a Tier 1 ratio of 8.9% prior to its plan of action, which made it a VERY well-capitalized bank (failed bank?). The bottom line is Project West could not become a reality unless the FDIC forced it. The only failure was the FDIC’s and other regulatory bodies in so many ways, and the use of the phrase “failed bank” to this day is a travesty, an injustice, and an outright twisting of the truth about WAMU’s financial position, especially in comparison to what JPM’s was at that time. That is my position as supported by the above.

For those that contend otherwise, straight from the FDIC (Last Updated: 10/23/2020).

Status of Washington Mutual Bank Receivership

"On September 25, 2008, the Federal Deposit Insurance Corporation (“FDIC”) was appointed the Receiver (“Receiver”) of Washington Mutual Bank ("WAMU"). The Receiver transferred substantially all WAMU's assets and liabilities to JPMorgan Chase Bank, N.A. ("JPMC") pursuant to a Purchase and Assumption Agreement dated September 25, 2008 - PDF("P&A Agreement"). WAMU, which was the largest failure of an insured depository institution in the history of the FDIC, had $307 billion assets, $188 billion deposits, and over 2,300 branches in fifteen states when it failed. The resolution of WAMU through the P&A Agreement was completed at no cost to the Deposit Insurance Fund."

https://www.fdic.gov/resources/resolutions/bank-failures/failed-bank-list/wamu-settlement.html

Review post 185194. It may put matters into perspective.

The bashers never post anything that makes sense. Just throwing stuff against the wall to see if it sticks and to keep the little tribe happy.

Maybe I missed something. Show me the reference from the article you posted ("A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates) where J. Cotropia pumped ITV-1. Or, better yet, Charles?

I think SAGA has much more to lose here than ENZC. SAGA needs to close a deal or return investor capital. The latter has consequences. I believe we have the upper hand in negotiating for value, especially with upcoming events during the next few months.

There’s a claim here that SAGA is a pump/scam. Until a binding agreement is in place, then and only then does SAGA need to ensure capital is available to execute the deal. I think SAGA has investor interest but ENZC isn’t done negotiating and ammunition is looming in addition to squeezing SAGA to its very last extension for our benefit. The timing for all of this to come together with maximum potential for ENZC seems very well coordinated.

Pending positive results being announced from the Africa studies, the $450M figure can be multiplied significantly. This is how the game of cat and mouse is played. Time will ultimately reveal the outcome and patience is your partner.

Dr. Chandra’s tweet reaffirmed what was previously PR’d. My recollection also is that VIRO and BGEN were set up as licensing vehicles. Hence, even though they’re being sold, my thoughts are that their licensing authorizations have been granted by ENZC which has a link to the Zhabilov Trust as the only and ultimate owner of the patents. Hence, VIRO and BGEN don’t own the technology and ENZC still has great value even in a state of not having assets or operations, AIMO. Just following the trail of info, that has been provided over time.

Catpole, if I didn’t know any better I’d say that you’re a mind reader. However, I believe our minds were forged from the same blueprint.

Shells are all about creating value. What are SPACS? Essentially, shells.

I highly doubt ENZC will be left to rot without any further use. As a publicly traded entity, even if on the OTC Markets, it is a financial vehicle that can be used to spin-off assets. Own the company to own the spun-off entities or assets sold through negotiated deals.

Thanks DOGONE. ENZC is flexing some of its muscles like Underdog.

D3Cam,

With the little you just said, you said more than a lot.

No.

Did we know ALL the details when BioClonetics and ENZC announced a non-binding letter of agreement? What about when it was announced the agreement was binding? Did people know ALL the info. when they took the mRNA COVID-19 jabs?

For those of us that are and have been Bullish since the .000’s and higher, we took the Company’s info. at face value and did DD regarding the scientific basis for what ENZC PR’d along the way.

Remember when there were doubts, and likely bashes, that ENZC would ever have a product that it would actually sell (IPF Immune)? It was said it would never be sold by a pharmacy or large chain store. I guess Walmart is irrelevant and Amazon is relatively unknown (sarcasm). What a scam (sarcasm)!

You either saw and see unrealized value or not. Period!

FrankMD,

This is another iteration of a perspective that CC and company haven’t sold themselves and shareholders short. To think that $250M (now $450M) was all that would be accepted for his, his brother’s, and others’ life work (applicable to some) was never a remote possibility in my mind.

The estimated enterprise value also doesn’t include Clone 3 in my opinion. Assuming only $10B in revenues over 11 years would put the Present Value of Future Money at $5.4B given certain assumptions. We were informed that Clone 3’s estimated revenues over 11 years to be $105B (so a little more than 10X the PV calculation of $5.4B on only $10B). Enterprise Value takes debt into consideration and we don’t have audited financials or know what the future debt profile of the Company looks like. Nonetheless, the point here is that ENZC is SEVERELY undervalued as MAGA_Patriot and others have repeatedly pointed out. This isn’t on Wall Street’s radar…yet.

While this has been a journey of limited information, bumps, setbacks, and attacks of different kinds, my firm and unwavering opinion since I first bought shares is that all these roads lead to $$$ and a lot of it, other than what was able to be made along the way.

We’re charting waters that haven’t been navigated and the view of the horizon is quite pleasing. Looking forward to updates from Africa and the SPAC deal which I’m extremely confident will materialize.

Agreed falon. I’ve been envisioning different scenarios of what can play out but there’s no use in speculating because too much is under NDA and that’s why we’re only getting bits and pieces in my opinion. However, understanding what a SPAC is and how the process works could give doubters some hope or change their perspective.

A SPAC’s life begins with its initial formation, followed by its IPO, its search for a target, a shareholder merger vote, and, finally, the close of an acquisition (or the return of the SPAC’s proceeds to investors).

https://www2.deloitte.com/content/dam/Deloitte/us/Documents/audit/us-private-company-CFO-considerations-for-SPAC-transactions.pdf#:~:text=Life%20Cycle%20of%20a%20SPAC%20A%20SPAC’s%20life,the%20return%20of%20the%20SPAC’s%20proceeds%20to%20investors%29.

Here’s an alternative read: https://www.cohnreznick.com/insights/the-special-purpose-acquisition-company-lifecycle

From the above link:

De-SPACing
The de-SPACing process requires the buyer to obtain shareholder approval in accordance with SEC regulations. While these regulations are more complex than can be covered in detail here, typically the process includes the commitment of the founders shares to the acquisition, a redemption offer whereby SPAC shareholders can redeem their shares, and the filing of Form 8-K, which is effectively a registration statement for the transaction. It contains the information that would be filed in a Form 10, or “General Form for Registration of Securities,” which registers securities for trading in U.S. exchanges.

As shareholders in SAGA, it’s possible the shares will lose value when the merger is completed due to a redemption offer whereby SPAC shareholders can redeem their shares. Some investors are in for the short-term and others take a long-term approach. Or you can hedge by taking money off the table and letting the rest ride.

Understanding the above, it’s not out of the realm of things that SAGA, as a company with operations and two entities that represent IP and product, won’t eventually merge with or be part of a buyout scenario with ENZC. It will allow ENZC to uplist and management will officially be back together under one corporate roof. The question is what that transaction would look like? It’s possible that a different SPAC could be used to absorb both of them for reunification. Lots of possibilities. You just have to believe this is real and there’s value in it.

So, is ENZC being kept at a low share price purposely by higher powers? Yes, it very well may be and that can work to our benefit in some ways but not others. At a share price of .05 and on a fully diluted basis the Company’s market value would be $195M or about $150.54M at the current outstanding share count. Even if ENZC’s revenues from Clone 3 were only $10B in the next 11 years, the Net Present Value using an interest rate of 5.75% would be much greater than $150M or $195M.

Do you think you know what you own?

By the sound of the KLIC

Your comments are not amusing and demonstrate a lack of common sense IMO.

To answer your question consider the following about the so-called competition.

The Long History of mRNA Vaccines

Messenger RNA, or mRNA, was discovered in the early 1960s; research into how mRNA could be delivered into cells was developed in the 1970s. So, why did it take until the global COVID-19 pandemic of 2020 for the first mRNA vaccine to be brought to market?

The early years of mRNA research were marked by a lot of enthusiasm for the technology but some difficult technical challenges that took a great deal of innovation to overcome.

The biggest challenge was that mRNA would be taken up by the body and quickly degraded before it could “deliver” its message—the RNA transcript—and be read into proteins in the cells.

The solution to this problem came from advances in nanotechnology: the development of fatty droplets (lipid nanoparticles) that wrapped the mRNA like a bubble, which allowed entry into the cells. Once inside the cell, the mRNA message could be translated into proteins, like the spike protein of SARS-CoV-2, and the immune system would then be primed to recognize the foreign protein.

(Article continues)

https://publichealth.jhu.edu/2021/the-long-history-of-mrna-vaccines

Successful drugs and therapies aren’t developed, tested, and marketed in a matter of a few years. Oh, by the way, 1996 came well after the 70’s.

BonnieMac, the simple one word answer is Africa and we were provided with a roadmap or preview well before the April PR.

Here’s a near 27 year old publication.

J Acquir Immune Defic Syndr Hum Retrovirol
. 1996 Jul;12(3):221-32. doi: 10.1097/00042560-199607000-00002.

A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates

J Cotropia 1 , K E Ugen, S Kliks, K Broliden, P A Broliden, J A Hoxie, V Srikantan, W V Williams, D B Weiner
Affiliations expand
PMID: 8673526 DOI: 10.1097/00042560-199607000-00002

Abstract

A potential component that may be useful for passive immunotherapy for HIV-1 is human monoclonal antibodies (HumAbs) possessing potent anti-HIV-1 activity that is directed against conserved regions of the envelope glycoprotein. Such antibodies would, in principle, have the ability to neutralize diverse isolates of HIV-1. To develop such reagents, hybridomas were derived by initial Epstein Barr virus transformation of peripheral blood mononuclear cells (PBMCs) from an asymptomatic HIV-1 seropositive donor followed by fusion with heteromyelomas, and secreted anti-HIV-1 antibodies were further characterized. The specificity of one HumAb, designated as clone 3, was determined by enzyme-linked immunosorbent assay (ELISA) and Western blotting analyses that indicated reactivity to the transmembrane envelope glyco-protein gp41. Synthetic pentadecapeptides overlapping by 10 amino acids were utilized for epitope mapping of clone 3; a decapeptide GCSGKLICTT in the transmembrane gp41 was identified as the epitope. Clone 3 bound to SupT1 cells infected with HTLV-IIIB in fluorescent activated cell sorting analysis. In addition, in vitro biological assays demonstrated that clone 3 possessed neutralization reactivity against diverse laboratory isolates as well as an AZT-resistant isolate. Therefore, clone 3 reactivity defines a conserved neutralizable site on the HIV-1 transmembrane glycoprotein. Clone 3 and the conserved immunogenic epitope on gp41 could be useful in passive and active immunotherapy for the acquired immunodeficiency syndrome (AIDS).

https://pubmed.ncbi.nlm.nih.gov/8673526/

The following question is being asked rhetorically to the entire message board. What is Enzolytics doing in Africa? Seriously speaking, I highly doubt it’s to promote a scam and sell shares. Instead, it’s about human trials. Decide if you want to buy, hold, sell, or none of the previous based on your risk tolerance, level of interest, understanding of this information, or whatever criteria you’d like to involve.

To all the naysayers claiming scam, calls have been made on this board well over a year ago that this was going to .000’s and would be shut down by the SEC. While I can’t guarantee any company wouldn’t go bust, be shut down, or violations of SEC laws wouldn’t be exposed, there are Big Board companies that are fined and found to be non-compliant with reporting standards and have engaged in possibly criminal behavior that ended up being settled by lawyers for pennies or much less than a penny on the dollar.

I am a long-holder, don’t believe this is a scam in the least, and am fully convinced the as of yet untapped potential commercial significance is enormous and the stock price is not reflective of the progression and Company’s activities of the last three or so years in addition to the research and efforts of Joseph Cotropia during his lifetime. Time will be the revealer and truth-teller. If you claim otherwise, go speak to Samsung Bilologics, Intel Corporation, Twist Biopharma, or Dr. Fauci himself.

Here’s a means to validate to what extent Enzolytics (via BioClonetics and Joseph Cotropia) has developed and contributed valuable information, technology, and research to Science and Medicine and to the world at large.

Of specific interest to some may be https://www.nature.com/nm/volumes to review the November 2001 publication.

OUR TECHNOLOGY HAS BEEN VALIDATED

In Vitro Testing Has Demonstrated the Neutralizing Capability of Our Monoclonal Antibody Clone 3

The ability of HIV to mutate renders anti-retroviral therapies ineffective against HIV in many cases. Because the Company's monoclonal antibody therapies target a portion of the virus that does not change, such mutations are not expected to affect the monoclonal antibody therapy.

Significant testing demonstrates the basis for this expectation. Specifically, in in vitro tests conducted in five independent laboratories, CLONE 3 has been tested against 43 clinical HIV isolates (strains) of the virus. CLONE 3 has demonstrated that it successfully neutralizes 41 of them (100% effective against over 95% of the HIV strain against which it was tested).

Presently, CLONE 3 is the only human monoclonal antibody found to neutralize the Clade C isolate found in Africa, China and India. CLONE 3 also neutralizes the Clade B isolate that is predominate in North America and Europe. In view of these test results, the Company is moving forward with animal and human trials to establish CLONE 3 as a significant means for treatment of those that have HIV/AIDS and to produce a vaccine against HIV.

These results were the product of testing in 5 independent laboratories. In tests conducted at the University of California at San Francisco (by Jay Levy, M.D.), CLONE 3 Antibody was shown to have in vitro neutralization effect against geographically distinct clinical HIV (primary) isolates. Research conducted at four additional international institutes has confirmed these results of in vitro neutralization. In total, the neutralizing capabilities of CLONE 3 have been verified at the following 5 laboratories:

1. University of California, San Francisco, CA, USA (Jay Levy, M.D.)

2. University of South Florida, Tampa, FL, USA (Kenneth Ugen, Ph.D.)

3. Polymun Scientific, GmbH, Vienna, AUSTRIA, (Hermann Katinger, Ph.D.)

4. Duke University, Durham, NC, USA (David Montefiori, Ph.D.)

5. Dana Farber Cancer Institute (DFCI), Harvard

Medical School, Boston, MA, USA, (Ruth Ruprecht, M.D., Ph.D.)

In these tests, Clone 3 neutralized [at IC90] 41 of 43 (>95%) of the clinical HIV-1 group M, N, and O isolates. Clone 3 neutralized 3 of 3 group O HIV isolates tested at 10 µg/ml in PBMC-based assay. In another study of Clone 3 tested against one group N primary HIV-1 isolate, results indicated that the IC90 for Clone 3 versus the HIV primary isolate YBF30 was 3.72 µg/ml. Further, Clone 3 has also been demonstrated to effectively neutralize 4 of 4 virulent pediatric South African clade C isolates [ZA349, ZA562, ZA600, ZA737]; and at 10 µg/ml, neutralize [IC99] a pediatric Zambian clade C HIV-1157, as well as the simian immunodeficiency virus construct SHIV-1157ip. Therefore, of the 43 HIV isolates against which Clone 3 has been tested, it neutralized 41 (over 95%).

Clinical Evidence of Effectiveness of Clone 3

Other laboratory evidence also supports the Company's conclusion that the Clone 3 antibody will neutralize HIV-1 in humans. This evidence includes the following five (5) laboratory findings in the publications listed:

- P.A. Broliden et al. reported that, in a group of HIV-infected infants born to HIV+ mothers, infants who lacked anti-KLIC (Clone 3) antibodies had a rapid progression to symptomatic AIDS.
Vanini et al. reported that deCreasing concentration of anti-KLIC (Clone 3) antibodies directly correlated with HIV disease progression.

- Loomis-Price et al., demonstrated that high antibody reactivity to the peptide containing the (Clone 3) immunogen epitope [KLIC] is associated with slow progression to AIDS.

- Dietrich et al. further validated the significance of the (Clone 3) epitope by reporting the presence of anti-KLlC antibodies identified in HIV+ blood plasma obtained from LTNPs who had normal T?cell counts, no opportunistic infections and were not taking any prescribed adjunct chemotherapeutics or anti-retroviral drugs.

- Cano et al. cited the BioClonetics publications on (Clone 3) mAb, noting that the human monoclonal anti-gp41 antibody was a neutralizing anti-HIV antibody that binds preferentially to a linear peptide in the immunodominant region. The authors found "a correlation between the presence of anti-linear peptide antibodies and endurance of infection".

The National Institute of Health (NlH) studies, conducted by Anthony Fauci et al., head of the NIH, and published in Nature Medicine November 2001, provide further validation of the efficacy of this linear amino acid epitope, KLIC, as a protective active vaccine immunogen.

As background for understanding how tests conducted by Dr. Fauci demonstrate that Clone 3 will be effective in humans, one must understand how Clone 3 actually neutralizes the HIV virus. Through collaboration with the Karolinska Institute in Stockholm, Sweden (Britta Wahren, M.D., Professor of Microbiology), the Company identified the linear minimal essential core epitope on the virus to which Clone 3 binds. As published in the Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology in 1996 (reference 3 in Appendix), this minimal core epitope is defined as the amino acid sequence KLIC, located on the portion of the virus designated as glycoprotein (gp) 41.

In Dr. Fauci's primate phage-display peptide vaccine studies, primates were vaccinated with a peptide immunogen represented as the linear KLVC rather than KLIC. (Fauci et al., Nature Medicine, Volume 7, Number 11, November 2001, pp. 1225-1231). KLVC is a linear peptide having a conservative amino-acid substitution of valine (V) for isoleucine (I). KLIC occurs in the native HIV-1 gp41 amino acid sequence and is essentially seen as the same immunogen.

The vaccinated primates produced an antibody [anti-KLVC] that is cross-reactive with linear peptide KLIC?an amino acid sequence on HIV gp41 (and SHIV gp41). When the primates were challenged with the SHIV virus [having the gp41 amino acid sequence KLIC], the vaccinated primates'although infected with SHIV were infected at a lower SHIV viral set point than the SHIV challenged non-vaccinated control primate. Moreover, the vaccinated primates retained normal T4 cell counts while the non-vaccinated control primate's T4 cell counts decreased and progressed to AIDS and death within 6 months of SHIV challenge. The KLVC vaccinated primates' health status were that of a Long-Term Non-Progressor (LTNP).

These tests demonstrate that the Clone 3 active vaccine component prevented progression to AIDS-like illness, and also supports the conclusion that the peptide of the Clone 3 epitope (KLIC) will be effective as an active vaccine against HIV/AIDS.

Additional evidence allows the company to project that its antibody will neutralize over 98% of the HIV viral strains (clades) worldwide based upon information confirmed by the U.S. Government’s National Laboratory HIV clinical isolate database at Los Alamos, NM. Specifically, to date, Los Alamos has currently reported 4,556 clinical HIV-1 variants or subtypes (February 2015). The company has determined that the site on the virus to which Clone 3 binds in the neutralization step (its epitope) is highly conserved in 98% of the HIV-1 viral strains. Based on this knowledge and other independent in vivo clinical-correlate evidence from five (5) additional independent research institutions, the company's proprietary antibody is expected to provide a safe immunotherapeutic long-term remission for people living with HIV/AIDS and an effective active vaccine that protects uninfected individuals from HIV infection.

http://bioclonetics.com/validation.html

Scam or the target of individuals or groups seeking to spread misinformation? Do you due diligence and know what you own.

Post 703635

7.2 was referenced by memory which I recalled incorrectly. 7.8 it was.

Agree 100% and thanks for pointing out the distinction between WMI (Washington Mutual, Inc. - holding company) and WAMU (Washington Mutual Bank).

As shareholders, we owned WMI and not Washington Mutual Bank as has been pointed out in the past by at least one, if not more posters.

The charter belonged to the holding company and was not within the OTS’s or FDIC’s (LOL @ FDICK) authority to seize it. Hence, illegal taking as was the taking of WAMU when it was IN FACT solvent.

jb,

I appreciate your positive feedback on my posts and am content to provide my perspective on certain matters.

Recently, I’ve had a bit of time and the desire to post so I’ve become more active but don’t see that continuing for an extended timeframe.

With regard to timing, I don’t care to speculate as F&R has been quite complicated. It’s been debated for years if the returns shareholders received truly represent the F&R judge Walrath referenced in the bankruptcy case. I repeat, the bankruptcy case. The bankruptcy case had no jurisdiction over trust assets, so how could Judge Walrath’s F&R reference have anything to do with anything bankruptcy-remote?

It is a documented fact that JPM was working on Project West as e-mails became available between Jamie Dimon and Sheila Blair discussing the matter. Why else would JPM have made an offer to buy WAMU? It was salivating over its branch network and deposits and JPM wanted to establish a West coast presence. What about WAMU’s charter? - the last of its kind. It was reviewing information about WAMU well before the so-called insolvency materialized so yes, they did a thorough job. The fact that JPM claims that they purchased more than $4 billion in cash which they believe was included in the $1.9 billion dollar purchase is asinine. JPM and Sheila Bair also thought the holding company would be game but we’re well aware of their plea to Congress after they came to realize it wouldn’t be the case. Do I believe they were trying to get hold of a big sausage? I sure do.

The point of posting what I did was to track the chain of ownership to XXXX.

Sausages are not hidden without twists, turns, degrees of separation (layering), and smoke screens.

Two Harbors Investment Corp. Announces Definitive Agreement to Acquire RoundPoint Mortgage Servicing Corporation

https://www.businesswire.com/news/home/20220803005902/en/Two-Harbors-Investment-Corp.-Announces-Definitive-Agreement-to-Acquire-RoundPoint-Mortgage-Servicing-Corporation

You’re welcome. The second paragraph wasn’t of interest?

Mr. Cooper, formerly Nationstar Mortgage Holdings Inc. was founded in 1994 and is headquartered in the Dallas, Texas, area.

Fortress (Fortress Investment Group LLC) acquired Nationstar in July 2006 and took the company public in March 2012. In 2017, Nationstar faced financial difficulties and was rebranded as Mr. Cooper.

Recently, servicing for loans has transferred from Mr. Cooper to Roundpoint Mortgage Servicing LLC with Step 4 of the loan transfer process taking place from June 11th to June 15th.
https://www.roundpointmortgage.com/newcustomers/mr-cooper

LOL! The not so reviewed ‘review’.

This is an admission of how the SEC doesn’t do its job. Or, maybe it did do its job by investing ZERO time on a nothing burger.

I think it’s way past time to take the lead foot off the “Old News” pedal. - i.e. Joseph Cotropia medical license revocation.

Your order status is your proof. Time of submission vs. time of execution. I don’t trade with ETrade but I would imagine it also shows the price of order execution request and resulting trade price.

That can be referenced if you call to speak to somebody.

What you will learn about me is as much as I care to know about you.

LOL@bone up

Time for you to press Reset because you’re on GSA boot loop.

It’s a well-known fact that you can’t discuss something in bankruptcy court that the court has no jurisdiction over.

On the matter of financial health, you couldn’t have a 7.2% Tier 1 ratio and be considered a “sick puppy” - not at that time.

The FDIC can’t guarantee that there won’t be any equity returns and that’s why the terminology used has been “it is not expected” - not definitive. The receivership is still open.

Hellooooooooooooooooo!

Can you say “orchestrated”? Sure, after all, it wasn’t deemed too big to fail. However, as we know, it was deemed just right to help prop the global financial system.

The Tier ratio was perfect for an unjust and extraordinarily unusual Thursday taking. How heroic did the FDIC make itself out to be announcing the “combination” of the two companies and that as of Friday morning operations would continue BAU? ‘All depositors are fully protected and there will be no cost to the Deposit Insurance Fund.’ Wait Sheila, what about the $14B deficit?

Cash is king and WAMU had loads of deposits which JPM was salivating over. $1.9B to assume the balance sheet of a solvent bank. The math doesn’t add up. But what do politicians and the FDIC know about math other than trying to take away something that didn’t and doesn’t belong to where it was gifted? As far as my education tells me, 7.2% is greater than 3.5%. Not a coincidence that the law was changed after the fact that now permits for holding companies to be taken over as well. Simple facts tell a different story than what played out.

You didn’t answer my first 2 questions, let alone the answer to the third is it’s a farce. After all, where is the asset list?

The GSA? I’m not hung up on that. The political machine is powerful, but so is payback.

That’s right Val! Your ENZC fortune will far exceed what you will draw in totality from your Canada Pension Plan.

Watching, waiting, and still holding.

Should be an interesting November as I expect it will really be revved by then.